Iqymune (Human Normal Immunoglobulin)

Iqymune is used in immunoglobulin replacement therapy and immune modulation across several clinical conditions.

• Primary immunodeficiency diseases: restores normal IgG levels to reduce infection frequency.
• Secondary immunodeficiency (e.g., chemotherapy‑induced): provides antibody support to prevent opportunistic infections.
• Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity.
• Kawasaki disease: reduces inflammation and risk of coronary artery aneurysms in acute phase.
• Guillain‑Barré syndrome: accelerates recovery by neutralizing pathogenic antibodies.

• Human Normal Immunoglobulin supplies a broad spectrum of polyclonal IgG antibodies that bind to pathogens, toxins and auto‑antigens. By neutralizing these targets, it prevents infection and modulates immune effector functions such as complement activation and Fc‑receptor signaling. The pooled antibodies also provide immunoregulatory effects that can down‑regulate pathogenic auto‑antibody production and inflammatory cytokine release, thereby restoring immune homeostasis in the patient.

Intravenous immunoglobulin therapy may be associated with a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate pain often occurring during or after infusion.
• Fever and chills: transient rise in temperature and shaking.
• Fatigue: general tiredness following administration.
• Nausea: mild gastrointestinal upset.
• Infusion‑related reactions: erythema, itching or mild hypotension.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Thromboembolic events: blood clots such as deep‑vein thrombosis or pulmonary embolism.
• Acute renal failure: sudden loss of kidney function, especially with high‑dose regimens.
• Aseptic meningitis: inflammation of meninges without infection.
• Hemolytic anemia: destruction of red blood cells.
• Severe thrombocytopenia: markedly low platelet counts.

Before initiating Iqymune therapy, several precautions should be observed to ensure patient safety.

• Baseline IgG assessment: measure serum immunoglobulin levels to determine need for replacement.
• Infusion rate monitoring: start at a low rate and increase gradually to reduce reactions.
• Renal function evaluation: adjust dosing or infusion speed in patients with impaired kidneys.
• IgA deficiency screening: avoid use in patients with anti‑IgA antibodies due to risk of anaphylaxis.
• Thrombotic risk assessment: exercise caution in individuals with a history of clotting disorders.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Normal Immunoglobulin can interact with other medicines, affecting their efficacy or safety.

Major Interactions (Avoid)

• Live attenuated vaccines: may be neutralized, reducing vaccine effectiveness.
• Concurrent IVIG products: risk of immunoglobulin overload and increased adverse events.
• High‑dose aspirin or NSAIDs: may heighten risk of renal impairment when combined with IVIG.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): IVIG can alter coagulation parameters, requiring INR monitoring.
• Corticosteroids: may mask infusion reactions, necessitating careful observation.
• Immunosuppressants (e.g., rituximab): timing adjustments may be needed to avoid reduced efficacy.